Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention

Circulation Journal

Volumn 70, Issue 10, 2006, Pages 1269-1274

  Young, Joon Hong ^a   Myung, Ho Jeong ^a   Sun, Ho Hwang ^a   Nam, Sik Yun ^a   Sang, Rok Lee ^a   Seo, Na Hong ^a   Kye, Hun Kim ^a   Hyung, Wook Park ^a   Ju, Han Kim ^a   Ahn, Youngkeun ^a   Jeong, Gwan Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Adrenergic antagonists; Coronary artery disease; Heart failure; Statins

Indexed keywords

CARVEDILOL; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RETROSPECTIVE STUDY; RISK REDUCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARBAZOLES; DEATH; DISEASE-FREE SURVIVAL; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; RETROSPECTIVE STUDIES; SIMVASTATIN; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33749008788     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1269     Document Type: Article

References (38)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
2. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med 2002; 3(Suppl 3): S2-S10.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
4. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
5. The Heart Protection Study Collaborative Group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo controlled trial. Lancet 2002; 360: 7-22.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
7. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004; 43: 642-648.
8. Krum H, McMurray JJ. Statins and chronic heart failure: Do we need a large-scale outcome trial? J Am Coll Cardiol 2002; 39: 1567-1573.
9. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-224.
10. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-2871.
11. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
12. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199.
13. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
14. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications: Part 2. Clin Chem 2001; 47: 418-425.
15. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphological and clinical determinants of procedural outcome with angioplasty for multivessel disease. Circulation 1990; 82: 1193-1202.
16. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29: 6-12.
17. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 2005; 69: 1477-1483.
18. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533-537.
19. Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 95: 619-622.
20. Ohno J, Watanabe E, Toyama J, Kawamura T, Ohno M, Kodama I. Risk stratification and survival in post myocardial infarction patients: A large prospective and multicenter study in Japan. Int J Cardiol 2004; 93: 263-268.
21. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93: 1124-1129.
22. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-119.
23. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
24. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
25. Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, et al. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J 2004; 68: 1067-1075.
26. Lacoste L, Lam JY, Hung J. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
27. Lefer DJ. Statins as potent anti-inflammatory drugs. Circulation 2002; 106: 2041-2042.
28. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984.
29. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin and plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.
30. Remme WJ. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol 2000; 23(Suppl 4): IV4-IV8.
31. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
32. Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, Bohm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999; 100: 346-353.
33. Kametani R, Miura T, Harada N, Shibuya M, Wang R, Tan H, et al. Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J 2006; 70: 321-326.
34. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569.
35. Naccarelli GV, Lukas MA. Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol 2005; 28: 165-173.
36. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
37. Yang YJ, Tang YD, Ruan YM, Zhang P, Zhou YW, Wang PH, et al. Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. Circ J 2003; 67: 159-162.
38. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J; OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004; 93: 603-606.